Study of three HIV drugs for adults with controlled HIV
Treatments studied
Part of Infections clinical trials.
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been on a stable oral HIV medication for at least 6 months.
- Your viral load (amount of HIV in your blood) must be under 50 copies/mL at screening and for at least 6 months before.
- You cannot have had certain serious infections or conditions like tuberculosis or severe liver disease.
- You cannot have used specific long-acting or IV HIV treatments before, like lenacapavir or certain antibodies.
- You must have good kidney and liver function, and no active hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people living with HIV who have undetectable viral loads to see how well a long-acting injectable medication (cabotegravir plus rilpivirine) works in real-world conditions. It may help understand if this injection-based treatment can reliably keep HIV controlled with fewer pills.
This trial tests a combination of two experimental drugs designed to 'shock and kill' hidden HIV in your body. It is for people with HIV-1 subtype B who are on successful ART and want to explore a potential step toward a cure.
This trial tests a combination of two drugs that may 'wake up' hidden HIV in your body's cells, so that your immune system or other treatments can then eliminate it. The goal is to shrink the HIV reservoir that remains even when you're on antiretroviral therapy.
This trial tests a long-acting injection called lenacapavir for children and teens with HIV who have tried other treatments and still have detectable virus. It may be an option if current medicines aren't working well enough.
This trial tests if two drugs, baricitinib and sirolimus, can help control HIV after stopping standard antiretroviral therapy (ART). It aims to see if these immune treatments allow patients to maintain viral suppression without daily pills.
This trial tests a new antibody called BNT351 to see if it is safe and how it affects the immune system. It is for adults who either do not have HIV, or have HIV and are not currently on HIV medications.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.